EOLS Q2 2021 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$26M+234.3% YoY

Gross Profit

$15M56.7% margin

Operating Income

-$15M-58.6% margin

Net Income

-$16M-59.8% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+113.2%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$240M

Total Liabilities

$134M

Stockholders' Equity

$106M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$8M	+234.3%
Gross Profit	$15M	$4M	+252.3%
Operating Income	-$15M	-$13M	-13.3%
Net Income	-$16M	-$21M	+26.1%

Revenue Segments

Product

$25M100%

Geographic Segments

CANADA

$702,000100%